Stock Ratings | With potential for gains exceeding 172%, Oppenheimer maintained its rating on Alumis (ALMS) at "outperforming the market" and raised its price target from $50 to $55.
Alumis Inc. ALMS | 0.00 | |
Rocket Pharmaceuticals, Inc. RCKT | 0.00 | |
Satellos Bioscience Inc MSLE | 0.00 | |
Opus Genetics, Inc. IRD | 0.00 | |
Senti Biosciences Holdings Inc SNTI | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
Oppenheimer: Maintaining Alumis' ( Alumis Inc.(ALMS.US) ) rating at "Outperform Market", while raising the price target from $50 to $55.
B of A Securities: Maintaining Rocket Pharmaceuticals' ( Rocket Pharmaceuticals, Inc.(RCKT.US) ) rating at "Buy", while raising the target price from $8 to $9.
HC Wainwright & Co.: Maintaining a "buy" rating on Satellos Bioscience ( Satellos Bioscience Inc(MSLE.US) ), while raising the price target from $1.2 to $11.
Cantor Fitzgerald: Initial rating for Opus Genetics ( Opus Genetics, Inc.(IRD.US) ) at "overweight", with a price target of $15.
Chardan Capital: Maintaining a "buy" rating on Senti Biosciences ( Senti Biosciences, Inc.(SNTI.US) ), while lowering its price target from $13 to $11.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| Alumis Inc.(ALMS.US) | to lift | $55.0 | $20.21 | 172.14% | Oppenheimer |
| Rocket Pharmaceuticals, Inc.(RCKT.US) | to lift | $9.0 | $3.445 | 161.25% | B of A Securities |
| Satellos Bioscience Inc(MSLE.US) | to lift | $11.0 | $5.91 | 86.13% | HC Wainwright & Co. |
| Immix Biopharma, Inc.(IMMX.US) | to lift | $15.0 | $8.58 | 74.83% | Mizuho |
| Calumet, Inc.(CLMT.US) | to lift | $60.0 | $35.04 | 71.23% | HC Wainwright & Co. |
| Opus Genetics, Inc.(IRD.US) | Initial classification | $15.0 | $4.35 | 244.83% | Cantor Fitzgerald |
| Senti Biosciences, Inc.(SNTI.US) | cut | $11.0 | $0.7718 | 1325.24% | Chardan Capital |
| Datavault AI(DVLT.US) | cut | $3.0 | $0.555 | 440.54% | Maxim Group |
| AmpliTech Group, Inc.(AMPG.US) | cut | $7.0 | $1.76 | 297.73% | Maxim Group |
| Laird Superfood, Inc.(LSF.US) | cut | $6.0 | $2.13 | 181.69% | Maxim Group |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Baird: Maintaining Advanced Energy Industries' ( Advanced Energy Industries, Inc.(AEIS.US) ) rating at "Outperform Market," while raising its price target from $315 to $360.
UBS: Upgraded its rating on Adecoagro ( Adecoagro S.A.(AGRO.US) ) stock to "buy", raising its price target from $8 to $16.2.
Oppenheimer: Maintaining Alumis' ( Alumis Inc.(ALMS.US) ) rating at "Outperform Market", while raising the price target from $50 to $55.
Scotiabank: Maintaining a "sector-match" rating for América Móvil ( America Movil SAB de CV Sponsored ADR Class B(AMX.US) ), while raising its price target from $19.5 to $21.8.
First Coverage
BMO Capital: Initial rating for CBIZ ( CBIZ, Inc.(CBZ.US) ) stock at "outperforms the market", with a price target of $33.
B. Riley Securities: Initial rating for Crescent Capital BDC ( Crescent Capital BDC, Inc.(CCAP.US) ) at "neutral", with a target price of $13.5.
Craig-Hallum: Initial rating for CryoPort ( CryoPort, Inc.(CYRX.US) ) stock at "buy", with a target price of $15.
reduction
Barclays: Maintaining a "Market-Similar Weight" rating for Adient plc ( Adient plc(ADNT.US) ), while lowering the price target from $27 to $26.
HC Wainwright & Co.: Maintaining a "buy" rating on Alumis stock ( Alumis Inc.(ALMS.US) ), while lowering the price target from $40 to $25.
Barclays: Maintaining Autoliv's ( Autoliv Inc.(ALV.US) ) rating at "overweight," while lowering the target price from $140 to $135
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk warning:
Investing involves risk, and securities prices can rise or fall, or even become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, and risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.